Colfax Corporation Form 10-Q Summary
Filing identity: The supplied filing is for Colfax Corporation, not Enovis CORP. It covers the three months ended April 3, 2020, with comparison to March 29, 2019. Results are unaudited and reflect continuing operations after the September 2019 sale of the Air and Gas Handling business.
Business Context and Reporting Period
- Continuing operations consisted of Fabrication Technology, principally under the ESAB brand, and Medical Technology, principally under the DJO brand.
- The DJO acquisition closed February 22, 2019; therefore, the 2019 comparison includes only 35 days of Medical Technology activity versus a full quarter in 2020.
- The quarter included six more reporting days than the prior-year quarter. COVID-19 impacts became significant beginning in mid-March 2020.
Financial Performance and Liquidity
| Metric | Q1 2020 | Q1 2019 | Change/Comment |
|---|---|---|---|
| Net sales | $816.4 million | $683.9 million | Up 19.4%; acquisition contribution was $199.5 million, offset by $43.3 million of existing-business decline and $23.7 million of foreign-exchange headwind |
| Gross profit / margin | $348.2 million / 42.7% | $261.0 million / 38.2% | Margin increased 450 basis points |
| Operating income / margin | $46.8 million / 5.7% | $2.3 million / 0.3% | Improved primarily from lower strategic transaction costs and the full-quarter DJO contribution |
| Net income from continuing operations | $8.9 million | $(21.5) million | Basic and diluted EPS of $0.06 versus $(0.17) |
| Net income attributable to Colfax | $4.5 million | $(52.0) million | Consolidated EPS of $0.03 versus $(0.39) |
| Adjusted EBITA | $95.5 million | $90.2 million | Non-GAAP margin declined to 11.7% from 13.2% |
| Operating cash flow | $56.2 million | $(72.3) million | Improved working capital and lower asbestos-related cash outflows contributed to the increase |
| Capital expenditures | $31.1 million | $24.4 million | Investing cash outflow was $37.3 million, including $7.8 million of acquisitions |
- Fabrication Technology sales were $525.5 million, down from $560.4 million; segment operating income was $69.0 million versus $70.6 million. Margin improved to 13.1% from 12.6%.
- Medical Technology sales were $290.8 million versus $123.5 million, reflecting the full-quarter DJO contribution. Segment operating income declined to $3.8 million from $10.7 million, while Adjusted EBITA increased to $30.7 million from $25.7 million.
- Cash and cash equivalents increased to $365.6 million from $109.6 million at December 31, 2019, primarily from a net $244.3 million increase in borrowings. Management reported $675 million available on the revolving credit facility and approximately $917 million of capacity under the credit agreement and other facilities.
- Total debt was $2.540 billion, up from $2.312 billion at year-end 2019. The weighted-average interest rate on Credit Facility borrowings was 2.95%; letters of credit outstanding totaled $119.8 million.
- The company remained in compliance with its credit covenants at April 3, 2020. The May 1, 2020 amendment subsequently relaxed leverage and interest-coverage thresholds and added potential collateral requirements.
Material Changes Versus the Prior Comparable Period
- Reported sales increased because 2020 included a full quarter of DJO results; existing-business sales declined 6.3% due primarily to COVID-19, and foreign exchange reduced sales by approximately 3%.
- Medical Technology sales were adversely affected by postponed elective procedures, reduced clinic activity, canceled sporting events and lower general activity levels.
- Fabrication Technology demand weakened in the Americas, Europe and India, with certain production facilities temporarily closed by government order.
- Gross margin improved mainly because of the higher-margin Medical Technology mix and lower DJO inventory fair-value charges.
- Strategic transaction costs fell to $0.9 million from $53.3 million in the prior-year quarter, while acquisition-related amortization and other non-cash charges increased to $35.8 million from $23.7 million.
- Foreign currency translation produced a $172.8 million other comprehensive loss, driving accumulated other comprehensive loss to $642.1 million.
- The company adopted the current expected credit loss standard on January 1, 2020, recording a $4.8 million after-tax reduction to opening retained earnings.
Outlook, Risks, Contingencies and Unusual Items
- Management expected continued sales pressure in the second quarter and possibly beyond, but stated that the duration and magnitude of COVID-19 effects could not reasonably be estimated.
- Temporary mitigation actions included salary reductions, furloughs and layoffs, reduced discretionary spending, deferred capital expenditures, lower supplier purchases and working-capital initiatives. These actions were expected to reduce Q2 cash outlays by at least $100 million.
- Management expected elective-procedure backlogs eventually to convert to revenue as healthcare access expanded, but could not predict the timing or extent of recovery. Fabrication Technology recovery was tied to facility reopenings, industrial GDP and steel consumption.
- The May 1 credit amendment increased the maximum total leverage ratio to 5.75:1.00 for June 30, 2020 and 6.50:1.00 for subsequent quarters through March 31, 2021, subject to the amendment’s provisions. It also permitted a cash deduction of up to $125 million in the leverage calculation and could require substantially all personal property and certain equity interests to secure the facility if gross leverage exceeded 5.00:1.00.
- Asbestos-related liabilities totaled $349.2 million, offset by approximately $322.1 million of current and long-term insurance assets and receivables. The company had 16,742 unresolved claims at quarter-end and cautioned that actual liabilities and insurance recoveries could differ materially from estimates.
- Other principal risks included high leverage and covenant compliance, variable interest rates, foreign exchange, supply-chain and commodity risks, goodwill and intangible-asset impairment, pension obligations, product liability, litigation, cybersecurity and international regulatory exposure.
Investor Verification Priorities
- Confirm the registrant identity: the filing text identifies Colfax Corporation, while the request metadata identifies Enovis CORP.
- Assess subsequent-quarter COVID-19 effects on elective medical procedures, industrial demand, facility operations, revenue and operating cash flow.
- Reconcile debt balances, revolver availability, borrowing costs and compliance with the amended leverage and interest-coverage covenants.
- Separate acquisition-driven growth from organic performance, particularly in Medical Technology.
- Review the sustainability of working-capital improvements and the company’s ability to fund debt service, restructuring, capital expenditures and asbestos-related obligations.
- Monitor potential impairment of goodwill and other long-lived assets, as well as changes in expected credit losses, insurance recoveries and asbestos liabilities.